TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed price. Currency in USD
22.93
-0.13 (-0.56%)
At close: 4:00PM EDT

22.95 +0.02 (0.09%)
After hours: 4:41PM EDT

Stock chart is not supported by your current browser
Previous close23.06
Open23.16
Bid22.95 x 3000
Ask23.09 x 1100
Day's range22.93 - 23.33
52-week range10.85 - 33.24
Volume4,488,700
Avg. volume11,404,271
Market cap23.354B
Beta1.11
PE ratio (TTM)N/A
EPS (TTM)-15.79
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2017-11-27
1y target est20.43
Trade prices are not sourced from all markets
  • FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
    Market Realist4 days ago

    FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%

    On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.

  • Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018
    Motley Fool5 days ago

    Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018

    Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.

  • 3 Warren Buffett Stocks Worth Buying Now
    Motley Fool7 days ago

    3 Warren Buffett Stocks Worth Buying Now

    These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.

  • 4 Warren Buffett Stocks to Buy in Q2 Earnings
    Zacks7 days ago

    4 Warren Buffett Stocks to Buy in Q2 Earnings

    We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.

  • Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
    Zacks9 days ago

    Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • Teva Announces Launch of Generic Version of Uceris in US
    Market Realist10 days ago

    Teva Announces Launch of Generic Version of Uceris in US

    On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.

  • Associated Press11 days ago

    Correction: Teva-US-HQ Move story

    TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zacks11 days ago

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
    Market Realist11 days ago

    Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

    As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.

  • Teva Presented New Data on Fremanezumab: What You Should Know
    Market Realist11 days ago

    Teva Presented New Data on Fremanezumab: What You Should Know

    During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.

  • Teva Pharmaceutical Stock in the Week Ended July 6
    Market Realist14 days ago

    Teva Pharmaceutical Stock in the Week Ended July 6

    On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.

  • Analyst Recommendations for Teva Pharmaceutical in July
    Market Realist14 days ago

    Analyst Recommendations for Teva Pharmaceutical in July

    Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.

  • Teva to Present New Data for Fremanezumab
    Market Realist22 days ago

    Teva to Present New Data for Fremanezumab

    Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

  • 3 Best Big Pharma Stocks of 2018 So Far
    Motley Fool24 days ago

    3 Best Big Pharma Stocks of 2018 So Far

    Are any of these biggest year-to-date winners smart picks for the long term?

  • Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
    Market Realistlast month

    Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical

    On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.

  • Teva to Discontinue a Fremanezumab Study on Cluster Headache
    Zackslast month

    Teva to Discontinue a Fremanezumab Study on Cluster Headache

    Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

  • A Look at Teva’s Generic Drugs Research Pipeline
    Market Realistlast month

    A Look at Teva’s Generic Drugs Research Pipeline

    Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.

  • Teva Scraps A Study In Cluster Headaches — And This Rival Benefits
    Investor's Business Dailylast month

    Teva Scraps A Study In Cluster Headaches — And This Rival Benefits

    Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.

  • Here's Why Alder Biopharmaceuticals Is Rising Today
    Motley Foollast month

    Here's Why Alder Biopharmaceuticals Is Rising Today

    Traders cheer after a rival drug maker decides to partially scrap a late-stage study. Here's what investors need to know.

  • Teva’s Key Drugs in Its Specialty Products Pipeline
    Market Realistlast month

    Teva’s Key Drugs in Its Specialty Products Pipeline

    Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.

  • Teva Stock Up ~27% YTD in 2018: What’s Driving the Stock Rally?
    Market Realistlast month

    Teva Stock Up ~27% YTD in 2018: What’s Driving the Stock Rally?

    On June 13, Teva Pharmaceutical Industries (TEVA) ended the trading day at a closing price of $24.33. TEVA stock was trading ~28.0% lower than its 52-week high of $33.80 reported on July 13, 2017. Currently, TEVA stock is trading higher than its 50-day moving average of $20.52 as well as its 200-day moving average of $19.05.

  • MarketWatchlast month

    Teva to end late-stage trial of chronic cluster headache treatment after disappointing results

    Shares of Teva Pharmaceutical Industries Ltd. dropped 1.4% in premarket trade Friday, after the drug maker said it will discontinue the phase 3 trial of its treatment for chronic cluster headaches, after ...

  • A Look at Teva Pharmaceutical’s Valuation Multiples in June
    Market Realistlast month

    A Look at Teva Pharmaceutical’s Valuation Multiples in June

    On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x. The company’s forward EV-to-EBITDA, which is a capital structure–neutral valuation measure, is 11.2x. This multiple is higher than the industry average of 10.3x.

  • Analysts’ Recommendations for Teva Pharmaceutical in June
    Market Realistlast month

    Analysts’ Recommendations for Teva Pharmaceutical in June

    Teva Pharmaceutical Industries (TEVA) has been in the news lately and is one of the most keenly watched stocks on Wall Street. Teva Pharmaceutical has reported positive developments with respect to its restructuring plan to restore its falling sales. On June 13, Reuters surveyed 29 analysts covering Teva.

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realistlast month

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.